ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Astellas Pharma and Dyno Therapeutics Sign Option and License Agreement contractpharma
December 03, 2021Will collaborate to develop next-gen AAV gene therapy vectors for skeletal and cardiac muscle. -
Astellas and Dyno Therapeutics to Collaborate on Research to Develop Next-Gen AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle AmericanPharmaceuticalReview
December 03, 2021Astellas Pharma Inc. announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus (AAV) vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap? platform. -
Astellas and Dyno Therapeutics to develop AAV gene therapy vectors Pharmaceutical-Technology
December 03, 2021Astellas Pharma has signed an option and licence agreement with Dyno Therapeutics to develop next-generation adeno-associated virus (AAV) gene therapy vectors for skeletal and cardiac muscle. -
Dyno, Roche Ink Gene Therapy Deal Worth up to $1.8B contractpharma
October 16, 2020Collaboration combines Dyno’s AI-powered AAV vector capabilities with Roche and Spark Therapeutics’ gene therapy capabilities.
Pharma Sources Insight January 2025
